New insulin boosts artificial pancreas performance in type 1 diabetes trial

NCT ID NCT05508061

Completed Disease control Sponsor: Inreda Diabetic B.V. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a faster-acting insulin (Lyumjev) works better than standard insulin (Humalog) in a dual-hormone artificial pancreas for people with type 1 diabetes. Twelve adults who already used the artificial pancreas took part. Each person used both insulins for 30 days to compare glucose control and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Insulin Lispro (Lyumjev and Humalog)
What this could lead to: If Lyumjev works better, it could improve blood sugar control and reduce high glucose episodes for people using an artificial pancreas.
What could go wrong: This is a small, early-stage trial with only 12 people. Results may not apply to everyone, and faster insulin could increase hypoglycemia risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Hospital Gelderse Vallei

Ede, Gelderland, 6716 RP, Netherlands
Rijnstate Hospital

Arnhem, Gelderland, 6815 AD, Netherlands
Slingeland Hospital

Doetinchem, Gelderland, 7009 BL, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.